Objective
- This lab study aimed to assess the drug delivery of a COPD triple therapy MDI with spacer, and seek feedback from COPD patients who were using MDIs with a specific spacer.
Methods
- Cascade Impactor testing was performed using Trimbow† beclomethasone dipropionate/formoterol fumarate/glycopyrronium bromide (B/F/G 100/6/12.5 mcg/actuation) pMDI, delivered 0s after actuation, simulating perfect but unlikely coordination.
- A more realistic 2s delay (to simulate misuse) was investigated for the MDI with Spacer (AeroChamber Plus* Flow-Vu* Spacer).
- Fine Particle Mass (μg<4.46μm ± sd) and Fine Particle Fraction(% <4.46μm ± sd) were assessed.
- Patient feedback data was received from 437 COPD patients from a voluntary UK/Canada database (myAERO*) comparing the main differences they experienced when using the Spacer with a pMDI compared to pMDI alone.
Results
Cascade Impactor Testing Results
Survey Results
- A survey of 437 COPD patients showed that 79% of patients reported greater confidence in medication delivery when using a spacer with their pressurized metered dose inhaler. 10% of patients perceived fewer emergency visits and experienced fewer side effects.
Conclusions
- These results suggest that the Spacer tested can enable effective MDI drug delivery, providing consistent delivery of the intended dose (even with poor coordination) and maximize fine particle delivery.
- The COPD patients surveyed provided positive feedback relating to confidence in medication delivery and some also reported less emergency visits / side effects.